This article is more than 5 years old. Information may no longer be current.

Metabolic syndrome does not hinder Ilumya efficacy in psoriasis

Metabolic syndrome status does not affect Ilumya efficacy, safety or drug survival in patients with moderate to severe chronic psoriasis, according to post hoc analyses from two phase 3 studies, reSURFACE 1 and 2.

Patients with or without metabolic syndrome were assigned Ilumya (tildrakizumab-asmn, Sun Pharma) 100 mg (n = 290 without metabolic syndrome; n = 79 with metabolic syndrome) or tildrakizumab 200 mg (n = 263 without metabolic syndrome; n = 67 with metabolic syndrome).

Seventy-nine patients with metabolic syndrome had a higher rate of preexisting cardiovascular disease and diabetes, as well as a higher median baseline weight and higher BMI.

A comparable number of patients achieved at least 75% improvement on the Psoriasis Area and Severity Index (PASI) at weeks 12 and 52 regardless of metabolic syndrome status in both tildrakizumab doses.

Treatment efficacy through week 52 was also comparable in patients regardless of metabolic syndrome status. Additionally, mean PASI reductions from baseline were similar in all patients and for both doses.

The percentage of patients with one or more serious adverse event or serious infection were also similar in all patients. For all patients on tildrakizumab 100 mg, the most serious adverse events were gastrointestinal and cardiac disorders and for patients taking tildrakizumab 200 mg, injury and/or procedural complications and nervous system disorders were reported. The most common reported treatment-emergent adverse event was infection, according to researchers.

Diabetes did not worsen after treatment. Moreover, weight increases were minimal among patients with or without metabolic syndrome across both doses and averaged at approximately 1 kg.

“Despite limitations, these results suggest efficacy, safety and drug survival of tildrakizumab are comparable in patients with psoriasis regardless of metabolic syndrome status,” Mark Lebwohl, MD, professor and system chair of dermatology at Mount Sinai Hospital, and colleagues wrote. – by Abigail Sutton

Disclosures: Lebwohl is employed by Mount Sinai, which receives research funds from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, LEO Pharma, MedImmune/AstraZeneca, Novartis, Pfizer, SCIderm, UCB, Valeant and ViDac and is a consultant for Allergan, Aqua, Boehringer Ingelheim, LEO Pharma, Menlo and Promius. Please see the study for all other authors’ financial disclosures.